NASDAQ:ACIU AC Immune - ACIU Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. $2.22 +0.03 (+1.37%) (As of 03/24/2023 08:50 PM ET) Add Compare Share Share Today's Range$2.16▼$2.2350-Day Range$2.14▼$2.4952-Week Range$1.68▼$4.84Volume86,500 shsAverage Volume172,979 shsMarket Capitalization$185.48 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AC Immune MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside485.6% Upside$13.00 Price TargetShort InterestHealthy0.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.26Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.78) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector551st out of 995 stocksPharmaceutical Preparations Industry259th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, AC Immune has a forecasted upside of 485.6% from its current price of $2.22.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.69% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AC Immune has recently decreased by 2.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 2.9 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AC Immune this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by InstitutionsOnly 16.78% of the stock of AC Immune is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.78) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AC Immune (NASDAQ:ACIU) StockAC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.Read More Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comAC Immune (NASDAQ:ACIU) Upgraded by StockNews.com to HoldMarch 20, 2023 | finanznachrichten.deAC Immune SA: AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine PipelineMarch 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 20, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Buy Rating for AC Immune SA (ACIU)March 20, 2023 | finance.yahoo.comAC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine PipelineMarch 20, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)March 18, 2023 | uk.investing.comAC Immune earnings missed by CHF0.56, revenue topped estimatesMarch 18, 2023 | seekingalpha.comAC Immune: Dementia-Focused Swiss Biotech With A Sad History Of FailuresMarch 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Paratek Pharmaceuticals (PRTK) and AC Immune SA (ACIU)March 17, 2023 | americanbankingnews.comAC Immune (NASDAQ:ACIU) Now Covered by Analysts at StockNews.comMarch 16, 2023 | finance.yahoo.comAC Immune Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 15, 2023 | msn.comAC Immune Earnings PreviewMarch 8, 2023 | finance.yahoo.comAC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023February 7, 2023 | finanznachrichten.deAC Immune SA: AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43February 7, 2023 | finance.yahoo.comAC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43January 26, 2023 | marketwatch.comAC Immune Shares Up 9% on Alzheimer's Vaccine Trial DataJanuary 26, 2023 | finance.yahoo.comAC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE TrialJanuary 18, 2023 | finanznachrichten.deAC Immune SA: AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's DiseaseJanuary 18, 2023 | finance.yahoo.comAC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s DiseaseJanuary 7, 2023 | finance.yahoo.comAC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29%December 27, 2022 | seekingalpha.comWhy I've Added A Full Position In AC Immune To My Tax Loss Selling BasketDecember 6, 2022 | seekingalpha.comAC Immune Could Reload On Upcoming ReadoutNovember 30, 2022 | finance.yahoo.comAC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further DevelopmentNovember 25, 2022 | finance.yahoo.comWill AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?November 23, 2022 | finance.yahoo.comAC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD ConferenceOctober 6, 2022 | benzinga.comAC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer's Disease and Down SyndromeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Company Calendar Last Earnings11/08/2021Today3/26/2023Next Earnings (Estimated)4/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+485.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,140,000.00 Net MarginsN/A Pretax Margin-1,797.91% Return on Equity-35.34% Return on Assets-32.49% Debt Debt-to-Equity RatioN/A Current Ratio11.16 Quick Ratio11.16 Sales & Book Value Annual Sales$4.12 million Price / Sales45.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.05Miscellaneous Outstanding Shares83,550,000Free Float79,709,000Market Cap$185.48 million OptionableNot Optionable Beta0.59 Key ExecutivesAndrea PfeiferChief Executive Officer & DirectorChristopher RobertsChief Financial Officer & Associate VP-FinanceOliver SolVP & Head-Clinical DevelopmentPiergiorgio DonatiChief Technical Operations OfficerMarie Kosco-VilboisChief Scientific OfficerKey CompetitorsLianBioNASDAQ:LIANXeris BiopharmaNASDAQ:XERSNuvectis PharmaNASDAQ:NVCTAadi BioscienceNASDAQ:AADIOptiNoseNASDAQ:OPTNView All CompetitorsInstitutional OwnershipMorgan StanleySold 26,730 shares on 2/15/2023Ownership: 2.335%Avidity Partners Management LPBought 50,524 shares on 2/15/2023Ownership: 0.389%Jane Street Group LLCBought 42,581 shares on 2/15/2023Ownership: 0.051%Virtu Financial LLCBought 35,501 shares on 2/15/2023Ownership: 0.042%Mariner LLCSold 4,869 shares on 2/15/2023Ownership: 0.018%View All Institutional Transactions ACIU Stock - Frequently Asked Questions Should I buy or sell AC Immune stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks. What is AC Immune's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price targets for AC Immune's stock. Their ACIU share price forecasts range from $10.00 to $16.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 485.6% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts. How have ACIU shares performed in 2023? AC Immune's stock was trading at $2.04 at the start of the year. Since then, ACIU shares have increased by 8.8% and is now trading at $2.22. View the best growth stocks for 2023 here. When is AC Immune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our ACIU earnings forecast. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV). When did AC Immune IPO? (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. What is AC Immune's stock symbol? AC Immune trades on the NASDAQ under the ticker symbol "ACIU." Who are AC Immune's major shareholders? AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (2.33%), Platinum Investment Management Ltd. (1.30%), Wells Fargo & Company MN (0.87%), Assenagon Asset Management S.A. (0.71%), Renaissance Technologies LLC (0.48%) and Avidity Partners Management LP (0.39%). How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AC Immune's stock price today? One share of ACIU stock can currently be purchased for approximately $2.22. How much money does AC Immune make? AC Immune (NASDAQ:ACIU) has a market capitalization of $185.48 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. How many employees does AC Immune have? The company employs 137 workers across the globe. How can I contact AC Immune? AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120. This page (NASDAQ:ACIU) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.